Skip to content

Movement Disorder in ICU

After the talk at PCICC_26 I've been wondering about the overlap between status dystonicus, or dystonia more wildly a condition normally seen in children/young adults, and us seeing it in adults.

My logic being that the same pathology that you would see in hypoxic ischaemic encephalopathy in children, is similar to what you might see post cardiac arrest etc.

Status dystonicus is a "life threatening movement disorder emergency" It is rare. There is no internationally agreed definition.

Its the end of a spectrum of worsening dystonia.

Dystonia is a hyperkinetic movement disorder, with repetitive twisting movements, postures, or both.

Key distinguising finding is it gets better with sleep.

It gets worse when trying to move

It's caused by:

  • dehydration
  • medication changes
  • infection
  • trauma
  • surgery
  • anaesthesia
  • stress
  • pain
  • constipation
  • 1/3 no cause found

That list above is for a paeds context, not adult ICU

Medicines to worry about causing it include:

  • haloperidol
  • metoclopramide
  • clonazepam
  • cloazapine

In our ICU context it would be a secondary dystonia (it's secondary acquired due to cerebral/brainstem/cord insult).In general its most common seen in CP

Status dystonicus - Practice Guide

It looks like the life threatening process is:

dystonia \(\rightarrow\) rhabdomyolysis \(\rightarrow\) renal failure and acidosis

from a complication side it looks like they say investigate and treat like rhabdo

differential include what you'd normally think of: - serotonin / nms/ malignant hyperthermia

but they also talk about paroxysmal autonomic instability, and acute dystonic reactions/oculogyric crises

They manage:

Pre status dystonicus / brittle dystonia

with higher sedation for sleep - chloral hydrate, and clonidine in fact they have clonidine as 1-5 \(\mu\)g/kg/dose 3 times daily

so they have: chloral hydrate clonidine chlormethiazole trimeprazine

all as options

they also talk about amitriptyline,

they also talk about baclofen and gabapentin and benzos

they talk about clonidine a lot when it comes to sedation / sleep

for stronger sedation they do talk about benzodiazepines, propofol, etc

they do talk about dystonia specific drugs, being used in combination:

  1. anticholinergic - trihexphenidyl
  2. dopamine blocker - haloperidol
  3. catecholamine blocker - tetrabenzine

they talk again about gabapentin and benzos, and baclofen and levodopa

Bigger picture wise, I guess I'm thinking about movement disorders post cardiac arrest and what they mean. Movement disorders after hypoxic brain injury following cardiac arrest in adults

Claude Generated Summary Of Chat:

tags: - critical-care - neuroprognostication - movement-disorders - cardiac-arrest created: 2026-07-01

Post-Cardiac-Arrest Movement Disorders

Summary

Four entities — status myoclonus, Lance-Adams syndrome, basal-ganglia movement disorders, and paroxysmal sympathetic hyperactivity — separated by timing, consciousness level, EEG/SSEP, and (for PSH) autonomic coupling. Distinguishing them matters more than the phenomenology itself, because their prognostic meanings diverge sharply.

Post-arrest movement disorders separate cleanly on three axes — timing, consciousness level, and EEG/SSEP — and getting that separation right matters more than the phenomenology itself. Status myoclonus (myoclonic status epilepticus) is the earliest: generalised, spontaneous myoclonus within 24–72h in a still-comatose patient, on a malignant, non-reactive or burst-suppressed EEG with absent cortical (N20) responses. It is among the commoner early motor findings (roughly 10–20% of comatose survivors) and remains one of the strongest poor-prognosis signs, being invariably associated with death in the pivotal hypothermia-era cohort (Fugate, 2010).1 Management is essentially that of status epilepticus (valproate/levetiracetam/clonazepam, escalating to anaesthetic infusions), but its dominant role is prognostic — it should never drive withdrawal in isolation, only alongside EEG background and SSEP.

Lance-Adams syndrome shares the substrate (myoclonus) but carries the opposite meaning, and the discriminators are a reactive/preserved EEG and intact brainstem and evoked responses. Early LAS shows generalised myoclonus within 96h but with a reactive EEG and preserved N20/localising responses, while classic (chronic) LAS emerges over days-to-weeks as consciousness returns, as multifocal, stimulus-sensitive cortical action myoclonus. Early LAS is rare — 1.5% (7/458) of consecutive arrests — yet around 43% reached a good functional outcome (CPC 1–2) at three months, which is precisely why it must be actively distinguished from status myoclonus (Aicua Rapun, 2017).2 Chronic LAS is managed with combination clonazepam, levetiracetam and primidone, signals disability rather than death, and remits in roughly half (Scheibe, 2020).3

Basal-ganglia movement disorders are the delayed group — dystonia, chorea/dyskinesia, akinetic-rigid parkinsonism, and hyperkinetic "storms" — appearing weeks to months later, often progressive, and anchored by bilateral striatal/pallidal signal change on MRI; the discriminator from the myoclonus syndromes is sustained hypertonia rather than shock-like jerks. In a screened neuro-ICU HIE cohort they affected about 26% (19/72), though this is a selected population and the unselected rate is lower (Scheibe, 2020).3 Hyperkinetic storms and status dystonicus respond promptly to levomepromazine or intrathecal baclofen, while otherwise treatment is phenotype-directed (anticholinergics, tetrabenazine or botulinum toxin for dystonia, a levodopa trial for parkinsonism, ICU sedation ± GPi deep brain stimulation for refractory storms). Outcome is best summarised as "unfavourable but often not devastating" — roughly 58% remission, with cognitive recovery outpacing physical (Scheibe, 2020).3

Paroxysmal sympathetic hyperactivity (PSH) is the mimic to hold separate: paroxysmal, stimulus-triggered dystonic posturing yoked to simultaneous sympathetic surges (tachycardia, hypertension, hyperthermia, tachypnoea, sweating) — that autonomic coupling is what distinguishes it from a primary basal-ganglia disorder, and the PSH-AM gives validated diagnostic criteria (Baguley, 2014).4 It is best characterised after TBI (around 10–30% of severe acquired brain injury) and remains poorly quantified and under-recognised after adult cardiac arrest, though hypoxic injury is an established cause; management is trigger reduction plus sympatholysis (gabapentin, clonidine/dexmedetomidine, propranolol, with benzodiazepines or opioids to abort paroxysms), and its presence independently signals worse neurological outcome and prolonged recovery (Meyfroidt, 2017).5 Practically, any delayed hypertonic/dystonic post-arrest patient warrants an EEG to exclude status, an autonomic-pattern check to exclude PSH, and an MRI to confirm basal-ganglia injury before the label is fixed.

  1. Fugate JE, Wijdicks EFM, Mandrekar J, Claassen DO, Manno EM, White RD, et al. Predictors of neurologic outcome in hypothermia after cardiac arrest. Ann Neurol. 2010;68(6):907–14. doi:10.1002/ana.22133. ↩

  2. Aicua Rapun I, Novy J, Solari D, Oddo M, Rossetti AO. Early Lance-Adams syndrome after cardiac arrest: prevalence, time to return to awareness, and outcome in a large cohort. Resuscitation. 2017;115:169–72. doi:10.1016/j.resuscitation.2017.03.020. ↩

  3. Scheibe F, Neumann WJ, Lange C, Scheel M, Furth C, Köhnlein M, et al. Movement disorders after hypoxic brain injury following cardiac arrest in adults. Eur J Neurol. 2020;27(10):1937–47. doi:10.1111/ene.14326. ↩↩↩

  4. Baguley IJ, Perkes IE, Fernandez-Ortega JF, Rabinstein AA, Dolce G, Hendricks HT. Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus on conceptual definition, nomenclature, and diagnostic criteria. J Neurotrauma. 2014;31(17):1515–20. doi:10.1089/neu.2013.3301. ↩

  5. Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721–29. doi:10.1016/S1474-4422(17)30259-4. ↩